ClinicalTrials.gg
Not yet recruitingNCT05921968Updated Jul 19, 2023

Effect of Lactoferrin Versus Intravenous Iron Sucrose in Treatment of Anemia

A Phase 4 interventional study of Intravenous iron sucrose and Lactoferrin in Iron Deficiency Anemia, sponsored by Ain Shams University. Not yet recruiting. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-07-19.

Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing iron sucrose in Anemia, Iron-Deficiency — 4 open to participants now, 5 under way, none of them phase 3. iron sucrose · Anemia, Iron-Deficiency.

Planned enrollment
6th of 17
100 · median 74
Started
2023
with 1 other
Phase 4
7 of 17
2 open now
Registered
12th of 17
by date
Lead sponsor
1 of 17
Ain Shams University

Among the 17 studies testing iron sucrose in Anemia, Iron-Deficiency, this one is the 6th largest by planned enrollment, is one of 2 that started in 2023, is one of 7 in phase 4, and was the 12th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

4 of the 17 studies testing iron sucrose in Anemia, Iron-Deficiency are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About iron sucrose

iron sucrose: first FDA approval 2000 (VENOFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing iron sucrose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

Iron deficiency is the most common nutritional deficiency and the most common cause of anemia. Anemia has a significant impact on the health of the fetus as well as that of the mother. It impairs the oxygen delivery through the placenta to the fetus and interferes with the normal intrauterine growth, leading to fetal loss and perinatal deaths. Anemia is associated with increased preterm labor (28.2%), preeclampsia (31.2%), and maternal sepsis.

The study aims to compare the effect of Lactoferrin versus intravenous iron sucrose for the treatment of iron deficiency anemia during pregnancy.

Read the detailed description

Iron deficiency is the most common nutritional deficiency and the most common cause of anemia. Anemia has a significant impact on the health of the fetus as well as that of the mother. It impairs the oxygen delivery through the placenta to the fetus and interferes with the normal intrauterine growth, leading to fetal loss and perinatal deaths. Anemia is associated with increased preterm labor (28.2%), preeclampsia (31.2%), and maternal sepsis.

The study aims to compare the effect of Lactoferrin versus intravenous iron sucrose for the treatment of iron deficiency anemia during pregnancy.

The study will include 100 pregnant women with moderate iron deficiency anemia. They will assigned randomly in to 2 groups. Each group will contain 50 patients.

The first group will receive intravenous iron sucrose (sacrofer 100mg/5ml)as 200 mg elemental iron in 100 ml 0.9 NaCl over 20-30 minutes up to the total dose -Total dose will be calculated from this equation=weight(kg)x(target Hb in g/dl-actual Hb in g/dl)x2.4+500 rounded up to the nearest multiple of 100 mg The second group will receive lactoferrin 100 mg twice daily orally before breakfast and before dinner (pravotin 100 mg sachets will be dissolved in ¼ glass of water). Patients will be advised to avoid coffee, milk products and antacid before and after the dose of lactoferrin.

  1. Baseline assessment:

All women in the study will be submitted to:

  1. Complete History Taking Including:

    • Personal history: This included name, age, duration of marriage, last menstrual period, parity, occupation and special habits.
    • 1st day of last menstrual period.
    • Estimated gestational age
    • Contraceptive history
    • Obstetric history Including:
    • Full details of previous pregnancies (Date, outcome, onset and mode of delivery, gestational age at delivery and any associated complication or history of similar disorder, spacing between each pregnancy.
  2. General Examination Included: Weight, height, body Mass Index (BMI), temperature, pulse, blood pressure, chest and cardiac examination, signs of anemia
  3. Abdominal Examination
  4. Fetal monitoring: To confirm fetal maturity and fetal wellbeing by non-stress test and biophysical profile.
  5. U/S investigation: To confirm gestational age and exclude associated congenital anomalies.

Investigations:

  • Complete blood sample (CBC), total iron binding capacity and Transferrin saturation will be done in Ain Shams Maternity Hospital Labs.
  • Serum ferritin will be sent to any private lab.
  • Kidney function tests and liver function tests. 2. Follow up assessment:

    • Anemic pregnant women will be followed up every 4 weeks until delivery.
    • In between visits, patients will be contacted via phone for monitoring of any side effects.

      1. End of study assessment:
  • the same laboratory tests will be done with monitoring of any signs or symptoms of anemia until Hb level > 11 g/dl
03

Conditions studied

  • Iron Deficiency Anemia

Keywords

  • Anemia in pregnancy
  • Lactoferrin
  • Iron Sucrose
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Pregnant women with iron deficiency anemia.
  • Microcytic hypochromic anemia, moderate anemia ( 8 to 9.9 g/dl) and S. Ferritin levels \<12 ng/dl as per WHO guidelines
  • Gestational age: - 13-26 weeks.
  • Singleton viable pregnancy
  • Lastly, agreement to participate and sign the was a basic prerequisite

Exclusion Criteria:-

  • Women with a history of anemia due to any other causes such as chronic blood loss, hemolytic anemia, and thalassemia (including thalassemia trait).
  • Severe anemia \<7 g/dl requiring blood transfusion, bronchial asthma, clinical and/or laboratory evidence of hepatic, renal, hematologic or cardiovascular abnormalities.
  • History of peptic ulcer.
  • to iron preparations and treatment with any other iron preparation in the last one month before study entry.
  • Suspected acute infection.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Intravenous Iron Sucrose group

    50 pregnant women will receive 200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose -The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg

    Drug: Intravenous iron sucrose

  • Active comparator
    Lactoferrin group

    50 pregnant women will receive lactoferrin 100 twice daily orally .

    Drug: Lactoferrin

Interventions

  • DrugIron sucroseStudies of Iron sucroseIron sucrose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose) o The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg

    Also known as: Intravenous iron sucrose(Sacrofer 100mg/5ml) was manufactured by Amoun company for pharmaceutical and chemical industry ,Egypt.

  • 100 mg twice daily orally before breakfast and dinner

    Also known as: lactoferrin 100 mg (Pravotin100 mg sachet)was manufactured by Hygint company for pharmaceutical and chemical industry,Egypt. Egypt) twice daily orally .

06

What researchers measure

Primary outcomes

  1. evaluate the effect of oral lactoferrin as compared to intravenous iron sucrose on the serum level of ferritin

    estimation serum ferritin level

    Time frame: 4 weeks

  2. evaluate the effect of oral lactoferrin as compared to intravenous iron sucrose on the serum level of hemoglobin

    estimation hemoglobin level

    Time frame: 4 weeks

Secondary outcomes

  1. evaluation of lactoferrin side effect

    assessment of the incidence rate of nausea, vomiting and GIT upset

    Time frame: 4 weeks

  2. the incidence rate of constipation

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Artym J, Zimecki M, Kruzel ML. Lactoferrin for Prevention and Treatment of Anemia and Inflammation in Pregnant Women: A Comprehensive Review. Biomedicines. 2021 Jul 27;9(8):898. doi: 10.3390/biomedicines9080898. PubMed 34440102 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Jan 2024, 5 months later.

Of 43 non-industry phase 4 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's planned 5 months is below that.

Counting every sponsor, half of 51 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2023
First posted
Jun 27, 2023
StartEst.
Jul 30, 2023
Primary completionEst.
Jan 1, 2024
CompletionEst.
Apr 1, 2024
Last update
Jul 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05921968
Responsible party
Amal A. Elkholy (lecturer of clinical pharmacy, Ain Shams University) — Principal investigator
First posted
Jun 27, 2023
Start date
Jul 30, 2023 (estimated)
Primary completion
Jan 1, 2024 (estimated)
Completion
Apr 1, 2024 (estimated)
Last update
Jul 19, 2023

Study contacts

Amal Elkholy, PhD
Contact
amalanas9@gmail.com
+201060355448
Lina EL-Saeed, master
Contact
linanabil1990@gmail.com
+201092554407
Nagwa Sabri, professor
study chair · Department of Clinical Pharmacy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iron sucrose · Lactoferrin

Start the discussion